Free Trial
→ You cannot escape this reality (From Porter & Company) (Ad)tc pixel Free SRNE Stock Alerts

Sorrento Therapeutics (SRNE) Competitors

Sorrento Therapeutics logo
$0.0005 0.00 (0.00%)
As of 05/22/2026 03:49 PM Eastern
Compare

SRNE vs. SXTC, UPC, ABP, ATXI, and ASLN

Should you buy Sorrento Therapeutics stock or one of its competitors? MarketBeat compares Sorrento Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sorrento Therapeutics include China SXT Pharmaceuticals (SXTC), Universe Pharmaceuticals (UPC), Abpro (ABP), Avenue Therapeutics (ATXI), and ASLAN Pharmaceuticals (ASLN). These companies are all part of the "pharmaceutical products" industry.

How does Sorrento Therapeutics compare to China SXT Pharmaceuticals?

Sorrento Therapeutics (NASDAQ:SRNE) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
China SXT Pharmaceuticals N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Sorrento Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

China SXT Pharmaceuticals has lower revenue, but higher earnings than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.43N/A
China SXT Pharmaceuticals$1.74M0.89-$3.30MN/AN/A

In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled China SXT Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
China SXT Pharmaceuticals Neutral

Summary

China SXT Pharmaceuticals beats Sorrento Therapeutics on 6 of the 7 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Universe Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Universe Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Universe Pharmaceuticals Neutral
Sorrento Therapeutics Neutral

Universe Pharmaceuticals has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Sorrento Therapeutics N/A N/A N/A

Universe Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.86M0.08-$3.67MN/AN/A
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.43N/A

Summary

Universe Pharmaceuticals beats Sorrento Therapeutics on 6 of the 7 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Abpro?

Sorrento Therapeutics (NASDAQ:SRNE) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Abpro has lower revenue, but higher earnings than Sorrento Therapeutics. Abpro is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.43N/A
AbproN/AN/A-$7.23M-$4.23N/A

In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled Abpro'saverage media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
Abpro Neutral

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Abpro shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 13.7% of Abpro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
Abpro N/A N/A -344.76%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Abpro
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Sorrento Therapeutics and Abpro tied by winning 4 of the 8 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Avenue Therapeutics?

Sorrento Therapeutics (NASDAQ:SRNE) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Sorrento Therapeutics' return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
Avenue Therapeutics N/A -471.57%-296.50%

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Avenue Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.43N/A
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A

In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
Avenue Therapeutics Neutral

Sorrento Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market.

Summary

Sorrento Therapeutics beats Avenue Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Sorrento Therapeutics compare to ASLAN Pharmaceuticals?

Sorrento Therapeutics (NASDAQ:SRNE) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
ASLAN Pharmaceuticals Neutral

ASLAN Pharmaceuticals has lower revenue, but higher earnings than Sorrento Therapeutics. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.43N/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

Sorrento Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sorrento Therapeutics' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

Summary

Sorrento Therapeutics and ASLAN Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Get Sorrento Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRNE vs. The Competition

Export
MetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$276K$309.61M$6.46B$12.34B
Dividend YieldN/AN/A2.76%5.28%
P/E Ratio0.00N/A21.2225.66
Price / Sales0.00189.70562.2886.31
Price / CashN/A22.4443.4956.67
Price / BookN/A4.7710.317.14
Net Income-$572.84M-$132.96M$3.57B$335.98M
7 Day PerformanceN/A2.45%6.43%4.15%
1 Month PerformanceN/A31.23%3.57%2.54%
1 Year PerformanceN/A77.59%34.07%35.06%

Sorrento Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRNE
Sorrento Therapeutics
N/A$0.00
flat		N/A-61.5%$276K$60.32MN/A800
SXTC
China SXT Pharmaceuticals
0.7784 of 5 stars		$1.60
-3.0%		N/A-99.3%$1.54M$1.74MN/A90
UPC
Universe Pharmaceuticals
0.8882 of 5 stars		$2.60
-1.9%		N/A-42.3%$1.46M$17.86MN/A220
ABP
Abpro
N/A$0.52
flat		N/AN/A$1.42MN/AN/A15
ATXI
Avenue Therapeutics
N/A$0.39
-18.3%		N/A+15.4%$1.28MN/A0.024

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SRNE) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel